StockNews.com downgraded shares of Meridian Bioscience (NASDAQ:VIVO – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
VIVO has been the topic of a number of other reports. HC Wainwright cut shares of Meridian Bioscience from a buy rating to a neutral rating and boosted their target price for the company from $30.00 to $34.00 in a research note on Friday, July 8th. William Blair downgraded Meridian Bioscience from an outperform rating to a market perform rating in a research report on Thursday, July 7th.
Get Meridian Bioscience alerts:Meridian Bioscience Stock Performance
Shares of Meridian Bioscience stock opened at $32.71 on Tuesday. The firm has a market capitalization of $1.43 billion, a P/E ratio of 33.04 and a beta of 0.28. The company has a current ratio of 3.52, a quick ratio of 2.60 and a debt-to-equity ratio of 0.07. The business's fifty day simple moving average is $30.99 and its 200 day simple moving average is $27.48. Meridian Bioscience has a 12 month low of $17.20 and a 12 month high of $34.38.
Insider Buying and Selling
In other Meridian Bioscience news, CEO John P. Kenny sold 13,559 shares of the business's stock in a transaction on Friday, June 24th. The shares were sold at an average price of $30.00, for a total transaction of $406,770.00. Following the sale, the chief executive officer now owns 265,131 shares of the company's stock, valued at approximately $7,953,930. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO John P. Kenny sold 13,559 shares of the firm's stock in a transaction that occurred on Friday, June 24th. The shares were sold at an average price of $30.00, for a total value of $406,770.00. Following the completion of the transaction, the chief executive officer now directly owns 265,131 shares in the company, valued at $7,953,930. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John P. Kenny sold 44,651 shares of the firm's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $29.72, for a total transaction of $1,327,027.72. Following the completion of the transaction, the chief executive officer now directly owns 265,131 shares of the company's stock, valued at $7,879,693.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 119,647 shares of company stock valued at $3,600,868. Company insiders own 2.30% of the company's stock.Institutional Investors Weigh In On Meridian Bioscience
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in shares of Meridian Bioscience by 218.6% during the 2nd quarter. FMR LLC now owns 1,950,987 shares of the company's stock valued at $59,350,000 after buying an additional 1,338,620 shares in the last quarter. Epoch Investment Partners Inc. bought a new stake in Meridian Bioscience during the fourth quarter worth about $14,348,000. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Meridian Bioscience by 129.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 455,665 shares of the company's stock worth $9,296,000 after purchasing an additional 256,729 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Meridian Bioscience by 44.6% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 640,418 shares of the company's stock valued at $16,625,000 after purchasing an additional 197,550 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Meridian Bioscience by 10.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,031,764 shares of the company's stock valued at $61,806,000 after buying an additional 197,000 shares in the last quarter. 94.72% of the stock is owned by hedge funds and other institutional investors.
Meridian Bioscience Company Profile
(Get Rating)
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
See Also
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.